CompletedNot Applicable

REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease

United States, Australia, Brazil1,006,361 participantsStarted 2020-12-15

Plain-language summary

This is a retrospective, multinational, non-interventional, observational study. A series of cohort studies will be conducted to assess the prevalence of undiagnosed stage 3 CKD in each region. The study will also assess the current state of CKD management in patients with undiagnosed CKD

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least two consecutive eGFR laboratory tests with values ≥30 and \<60 mL/min/1.73 m2 (Stage 3A or 3B) that are \>90 and ≤730 days apart. The index date is the date of the second eGFR measure meeting the criteria for stage 3 CKD * At least 12 months of continuous presence in the database or registration in the data prior to the first qualifying eGFR (for data sources with information on enrolment) * Age ≥18 years at index date Exclusion Criteria: * Solid organ transplant before the study index date * Any evidence of advanced CKD (stage 4, 5) based on CKD diagnostic codes, or renal replacement therapy before the index date

What they're measuring

Prevalence of undiagnosed stage 3 chronic kidney disease (CKD)

Timeframe: From 2015 assessed throughout the study, up to a maximum of 8 years

Time to CKD diagnosis

Timeframe: From second abnormal eGFR value until the date of CKD diagnosis or end of follow-up, assessed throughout the study period, up to a maximum of 5 years

Trial details

NCT IDNCT04847531

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-11-13

View on ClinicalTrials.gov More Chronic Kidney Disease trials